期刊
LEUKEMIA & LYMPHOMA
卷 59, 期 7, 页码 1586-1595出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/10428194.2017.1393671
关键词
Peripheral T-cell lymphoma; chemotherapy; hematopoietic progenitor cell transplant
资金
- Amgen
- AstraZeneca
- Bayer
- Celgene
- Merrimack
- Medimmune
- Merck Serono
- Sanofi
- Bristol-Myers Squibb
- Merck KgA
- Janssen-Cilag
- Sanofi Oncology
- Merck-Serono
- Novartis
We evaluated the outcomes for patients with peripheral T-cell lymphoma (PTCL) undergoing front-line chemotherapy at our institutions between 2002 and 2012. One hundred and fifty-six patients were eligible, comprising PTCL not otherwise specified (NOS) (n=50, 32.0%), angioimmunoblastic T-cell lymphoma (AITL) (n=44, 28.2%), anaplastic large-cell lymphoma (ALCL) ALK negative (n=23, 14.7%), ALCL ALK positive (n=16, 10.3%), and other (n=23, 14.7%). Most patients received CHOP (66.0%) and 13.0% received an autologous hematopoietic progenitor cell transplant (HPCT). With a median follow-up of 63.4 months, 5-year overall survival (OS) and progression-free survival (PFS) was 38.8% and 19.8% respectively. Independent risk factors for inferior OS were age >60 years, International Prognostic Index (IPI)2 and lack of complete response to induction. When responding patients were compared by receipt of an autologous HPCT versus not, HPCT was associated with improved PFS (p=.001) and OS (p=.046) and remained significant for PFS in multivariate analysis suggesting a possible therapeutic benefit.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据